Affiliation(s):
M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Malaysia;
moreAffiliation(s): M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Malaysia; Faculty of Pharmacy, University of Cyberjaya, Malaysia; Faculty of Pharmaceutical Sciences, UCSI University, Malaysia; Faculty of Medicine, Universiti Teknologi MARA, Malaysia;
less
Chee Ning WONG, Yang Mooi LIM, Kai Bin LIEW, Yik-Ling CHEW, Ang-Lim CHUA, Siew-Keah LEE. EGCG as a therapeutic agent: a systematic review of recent advances and challenges in nanocarrier strategies[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2400040
@article{title="EGCG as a therapeutic agent: a systematic review of recent advances and challenges in nanocarrier strategies", author="Chee Ning WONG, Yang Mooi LIM, Kai Bin LIEW, Yik-Ling CHEW, Ang-Lim CHUA, Siew-Keah LEE", journal="Journal of Zhejiang University Science B", year="in press", publisher="Zhejiang University Press & Springer", doi="https://doi.org/10.1631/jzus.B2400040" }
%0 Journal Article %T EGCG as a therapeutic agent: a systematic review of recent advances and challenges in nanocarrier strategies %A Chee Ning WONG %A Yang Mooi LIM %A Kai Bin LIEW %A Yik-Ling CHEW %A Ang-Lim CHUA %A Siew-Keah LEE %J Journal of Zhejiang University SCIENCE B %P %@ 1673-1581 %D in press %I Zhejiang University Press & Springer doi="https://doi.org/10.1631/jzus.B2400040"
TY - JOUR T1 - EGCG as a therapeutic agent: a systematic review of recent advances and challenges in nanocarrier strategies A1 - Chee Ning WONG A1 - Yang Mooi LIM A1 - Kai Bin LIEW A1 - Yik-Ling CHEW A1 - Ang-Lim CHUA A1 - Siew-Keah LEE J0 - Journal of Zhejiang University Science B SP - EP - %@ 1673-1581 Y1 - in press PB - Zhejiang University Press & Springer ER - doi="https://doi.org/10.1631/jzus.B2400040"
Abstract: Epigallocatechin-3-gallate (EGCG), a bioactive polyphenol abundant in green tea, has garnered significant attention for its diverse therapeutic applications, ranging from antioxidant and anti-inflammatory effects to potential anticancer properties. Despite its immense promise, the practical utilization of EGCG in therapeutic settings as a medication has been hampered by inherent limitations of this drug, including poor bioavailability, instability, and rapid degradation. This review comprehensively explores the current challenges associated with the application of EGCG and evaluates the potential of nanoparticle-based formulations in addressing these limitations. Nanoparticles, with their unique physicochemical properties, offer a platform for the enhanced stability, bioavailability, and targeted delivery of EGCG. Various nanoparticle strategies, including polymeric nanoparticle, micelle, lipid-based nanocarrier, metal nanoparticle, and silica nanoparticle are currently employed to enhance EGCG stability and pharmacological activity. This review concludes that the particle size of most of these formulated nanocarriers falls within 300 nm and their encapsulation efficiency ranges from 51% to 97%. Notably, the pharmacological activities of EGCG-loaded nanoparticles – such as antioxidative, anti-inflammatory, anticancer, and antimicrobial effects – are significantly enhanced compared to those of free EGCG. By critically analyzing the existing literature and highlighting recent advancements, this article provides valuable insights into the promising prospects of nanoparticle-mediated EGCG formulations, paving the way for the development of more effective and clinically viable therapeutic strategies.
Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article
Reference
Open peer comments: Debate/Discuss/Question/Opinion
Open peer comments: Debate/Discuss/Question/Opinion
<1>